Edwards Lifesciences Corp (EW)vsLumexa Imaging Holdings, Inc. Common Stock (LMRI)
EW
Edwards Lifesciences Corp
$89.95
-0.91%
HEALTHCARE · Cap: $52.33B
LMRI
Lumexa Imaging Holdings, Inc. Common Stock
$11.73
-1.92%
HEALTHCARE · Cap: $1.19B
Smart Verdict
WallStSmart Research — data-driven comparison
Edwards Lifesciences Corp generates 524% more annual revenue ($6.51B vs $1.04B). EW leads profitability with a 15.4% profit margin vs -2.7%. EW earns a higher WallStSmart Score of 51/100 (C-).
EW
Buy51
out of 100
Grade: C-
LMRI
Hold35
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+69.0%
Fair Value
$255.88
Current Price
$89.95
$165.93 discount
Intrinsic value data unavailable for LMRI.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Large-cap with strong market position
Strong operational efficiency at 29.8%
Conservative balance sheet, low leverage
Reasonable price relative to book value
Areas to Watch
Expensive relative to growth rate
Weak financial health signals
Premium valuation, high expectations priced in
Earnings declined 25.4%
0.0% earnings growth
Smaller company, higher risk/reward
Operating margin of 3.2%
ROE of -10.0% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : EW
The strongest argument for EW centers on Debt/Equity, Altman Z-Score, Market Cap. Profitability is solid with margins at 15.4% and operating margin at 29.8%. Revenue growth of 13.6% demonstrates continued momentum.
Bull Case : LMRI
The strongest argument for LMRI centers on Debt/Equity, Price/Book.
Bear Case : EW
The primary concerns for EW are PEG Ratio, Piotroski F-Score, P/E Ratio. A P/E of 54.0x leaves little room for execution misses.
Bear Case : LMRI
The primary concerns for LMRI are EPS Growth, Market Cap, Operating Margin.
Key Dynamics to Monitor
EW profiles as a mature stock while LMRI is a turnaround play — different risk/reward profiles.
EW is growing revenue faster at 13.6% — sustainability is the question.
EW generates stronger free cash flow (585M), providing more financial flexibility.
Monitor MEDICAL DEVICES industry trends, competitive dynamics, and regulatory changes.
Bottom Line
EW scores higher overall (51/100 vs 35/100), backed by strong 15.4% margins and 13.6% revenue growth. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Edwards Lifesciences Corp
HEALTHCARE · MEDICAL DEVICES · USA
Edwards Lifesciences is an American medical technology company headquartered in Irvine, California, specializing in artificial heart valves and hemodynamic monitoring.
Visit Website →Lumexa Imaging Holdings, Inc. Common Stock
HEALTHCARE · MEDICAL DEVICES · USA
Lumexa Imaging Holdings, Inc. owns and operates diagnostic imaging centres in the United States. The company is headquartered in Raleigh, North Carolina.
Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?